$Fractyl Health(GUTS.US)$Fractyl Health (NASDAQ:GUTS) reported quarterly losses of $(0.17) per share. This is a 97.84 percent increase over losses of $(7.87) per share from the same period last year. The company reported $33.000 thousand in sales this quarter. This is a 560.00 percent increase over sales of $5.000 thousand the same period last year.
A Revolutionary Step in Obesity Management: The Approval of Fractyl Health's Revita® Remain-1 Study. In a groundbreaking development for the field of obesity management, Fractyl Health has received FDA Investigational Device Exemption (IDE) approval for its pivotal Revita® Remain-1 study. This marks a significant milestone in providing durable weight maintenance solutions for patients after the discontinuation of GLP-1 based drugs. With ...
$Fractyl Health(GUTS.US)$Fractyl Health Receives FDA IDE Approval for the Revita Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs Globe Newswire 1-Apr-2024 6:00 AM
Fractyl Healthに関するコメント
In a groundbreaking development for the field of obesity management, Fractyl Health has received FDA Investigational Device Exemption (IDE) approval for its pivotal Revita® Remain-1 study. This marks a significant milestone in providing durable weight maintenance solutions for patients after the discontinuation of GLP-1 based drugs. With ...
Globe Newswire 1-Apr-2024 6:00 AM
まだコメントはありません